Abstract
Although therapy of CD30-positive lymphomas such as classical Hodgkin lymphoma and anaplastic large cell lymphoma has been improved considerably during the last decades, patients suffer from high toxicity of current therapeutic regimens. Since CD30 expression is very restricted, CD30-positive tumors are well suited for immunotherapeutic approaches. Several distinct immunotherapeutic approaches with chimeric, humanized, and bispecific antibodies as well as immunotoxins are already described. In this report, we give a short overview of CD30-targeting approaches in humans. Furthermore, we introduce two novel anti-CD30 fusion proteins consisting of the single chain variable fragment of the CD30 monoclonal antibody Ber-H2 and human interleukin-2, evaluate their biological activity in a human CD30-positive syngeneic murine model, and demonstrate the immunological mechanisms leading to tumor rejection by these reagents. The data indicate that there are several promising approaches in CD30-targeted immunotherapy. The findings of the anti- CD30 IL-2 constructs suggest that these fusion proteins are particularly useful to remove small, residual tumors.
Keywords: Immunotherapy, lymphoma, CD30, IL-2, fusion protein
Current Drug Targets
Title: Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo
Volume: 10 Issue: 2
Author(s): B. Hirsch, J. Brauer, M. Fischdick, C. Loddenkemper, S. Bulfone-Paus, H. Stein and H. Durkop
Affiliation:
Keywords: Immunotherapy, lymphoma, CD30, IL-2, fusion protein
Abstract: Although therapy of CD30-positive lymphomas such as classical Hodgkin lymphoma and anaplastic large cell lymphoma has been improved considerably during the last decades, patients suffer from high toxicity of current therapeutic regimens. Since CD30 expression is very restricted, CD30-positive tumors are well suited for immunotherapeutic approaches. Several distinct immunotherapeutic approaches with chimeric, humanized, and bispecific antibodies as well as immunotoxins are already described. In this report, we give a short overview of CD30-targeting approaches in humans. Furthermore, we introduce two novel anti-CD30 fusion proteins consisting of the single chain variable fragment of the CD30 monoclonal antibody Ber-H2 and human interleukin-2, evaluate their biological activity in a human CD30-positive syngeneic murine model, and demonstrate the immunological mechanisms leading to tumor rejection by these reagents. The data indicate that there are several promising approaches in CD30-targeted immunotherapy. The findings of the anti- CD30 IL-2 constructs suggest that these fusion proteins are particularly useful to remove small, residual tumors.
Export Options
About this article
Cite this article as:
Hirsch B., Brauer J., Fischdick M., Loddenkemper C., Bulfone-Paus S., Stein H. and Durkop H., Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354566
DOI https://dx.doi.org/10.2174/138945009787354566 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism Personalized Medicine in a Consumer Age
Current Pharmacogenomics and Personalized Medicine Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Patient Radiation Doses in Interventional Cardiology Procedures
Current Cardiology Reviews Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews Environmental Factors Contributing to Susceptibility to Tuberculosis
Current Respiratory Medicine Reviews Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets To Explore the Potential Targets and Current Structure-based Design Strategies Utilizing Co-crystallized Ligand to Combat HCV
Current Drug Targets Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Design of Peptide-Based Vaccines for Cancer
Current Medicinal Chemistry Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery HSF1, A Versatile Factor in Tumorogenesis
Current Molecular Medicine Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Radiolabeled Sugars Used for PET and SPECT Imaging
Current Radiopharmaceuticals Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Strategic siRNA Screening Approaches to Target Cancer at the Cancer Research UK Beatson Institute
Combinatorial Chemistry & High Throughput Screening Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design